Heron Therapeutics (HRTX) Finished Goods (2016 - 2026)

Heron Therapeutics has reported Finished Goods for 11 years, with the latest figure at $10.4 million in Q1 2026.

• For the quarter ending Q1 2026, Finished Goods rose 22.29% year-over-year to $10.4 million; the trailing twelve-month figure through Mar 2026 stood at $10.4 million (up 22.29% YoY), and the FY2025 full-year result was $6.9 million, up 10.36% from the prior year.
• Finished Goods for Q1 2026 stood at $10.4 million, up from $6.9 million in the prior quarter.
• The five-year high for Finished Goods was $22.0 million in Q3 2022, with the low at $6.2 million in Q4 2024.
• Historically, Finished Goods has averaged $12.3 million across 5 years, with a median of $10.4 million in 2026.
• Annual changes were most pronounced in 2022 — Finished Goods jumped 199.22% — and 2024, when it sank 58.01%.
• Heron Therapeutics' Finished Goods stood at $18.7 million in 2022, then tumbled by 47.0% to $9.9 million in 2023, then sank by 37.11% to $6.2 million in 2024, then rose by 10.36% to $6.9 million in 2025, then soared by 50.5% to $10.4 million in 2026.
• The last three Finished Goods figures came in at $10.4 million (Q1 2026), $6.9 million (Q4 2025), and $10.9 million (Q3 2025), per Business Quant data.